drugset

drugset / Trial / NCT00809276

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

NCT00809276 ↗

Phase 1/2 Completed 92 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Fred Hutchinson Cancer Center · collab M.D. Anderson Cancer Center · collab Otsuka Pharmaceutical Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.

Timeline

Start: 2009-05
Primary completion: 2011-12
Completion: 2011-12

Publications

Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014 Nov 1;32(31):3497-505. doi: 10.1200/JCO.2013.54.0625. Epub 2014 Sep 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	50 mg/kg	—
Background	Busulfan	Small molecule	—	Intravenous
Background	Fludarabine	Small molecule	—	Intravenous

Indications